Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical trial of INT301 to evaluate the safety of INT301 for long term treatment of peanut allergies

Trial Profile

A clinical trial of INT301 to evaluate the safety of INT301 for long term treatment of peanut allergies

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 20 Nov 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs INT 301 (Primary)
  • Indications Peanut hypersensitivity
  • Focus Adverse reactions
  • Most Recent Events

    • 20 Nov 2018 New trial record
    • 08 Nov 2018 According to an Intrommune Therapeutics media release, company look forward to submitting IND and expected to start this study in 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top